Innovating Works

IPL

Desconocido
ERA4TB: EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms...
2019-12-12 - 2025-12-31 | Financiado
FAIR: FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG RESISTA... INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020: H2020-SC1-BHC-2018-2020 Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with...
2019-12-06 - 2025-06-30 | Financiado
PERISCOPE: PERtussIS COrrelates of Protection Europe Sofia ref. 115910 INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage Pertussis vaccines have been very successful in reducing the global burden of pertussis-related disease. However, in the last decade there h...
2016-08-01 - 2022-08-31 | Financiado
ImmunoBile: Bile acid immune metabolism lipid and glucose homeostasis INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020: ERC-2015-AdG The role of chronic inflammation in obesity, metabolic and cardiovascular diseases is increasingly recognized. Bile acids (BA), synthesized...
2016-06-28 - 2022-02-28 | Financiado
CoSTREAM: Common mechanisms and pathways in Stroke and Alzheimer s disease. INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020: H2020-PHC-2014-2015 Common mechanisms and pathways in Stroke and Alzheimer's disease. It has long been recognized that stroke and (Alzheimer’s Disease) AD often...
2015-12-09 - 2021-05-31 | Financiado
TBVAC2020: TBVAC2020 Advancing novel and promising TB vaccine candidates from discovery to preclinical and ear... INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020: H2020-PHC-2014-2015 The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccin...
2014-12-03 - 2019-06-30 | Financiado
P16 AND METABOLISM: The role of p16INK4a in the development of obesity and insulin resistance INSTITUT PASTEUR DE LILLE FONDATION tramitó un FP7: Genome-wide association studies have linked the CDKN2A locus to an increased risk of Type 2 Diabetes (T2D), which is mostly accompanied by i...
Financiado
RESOLVE: A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with meta... INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7: Through combining basic pre-clinical and clinical research, network analysis and computational modelling, RESOLVE aims at resolving the dist...
Financiado
NEWTBVAC: Discovery and preclinical development of new generation tuberculosis vaccines INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7: With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An e...
Financiado
HOMITB: Host and microbial molecular dissection of pathogenesis and immunity in tuberculosis INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7: Tuberculosis (TB) is a leading public health problem. About half of the 10% of Mycobacterium tuberculosis-infected individuals develop overt...
Financiado
BIOMARCARE: Biomarker for Cardiovascular Risk Assessment in Europe INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7: Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond Eur...
Financiado
NANOREG: A common European approach to the regulatory testing of nanomaterials INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7: The innovative and economic potential of Manufactured Nano Materials (MNMs) is threatened by a limited understanding of the related EHS issu...
Financiado
TB PAN-NET: Pan European network for the study and clinical management of drug resistant tuberculosis INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7: This proposal will establish an integrated and synergistic network to address the challenge of multiple drug resistant tuberculosis (MDR-TB)...
Financiado
THESCHISTOVAC: The targeted development of a new generation Vaccine for Schistosomiasis INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7: The aim of this project is to develop a new generation vaccine for schistosomiasis. The vaccine will be based on exposed proteins and/or gly...
Financiado
AGEDBRAINSYSBIO: SYSTEMS BIOLOGY OF PATHWAYS INVOLVING BRAIN AGEING INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7: In spite of valuable approaches applied to get a broad understanding of genetic, epidemiologic and molecular and system-level biological pri...
Financiado
HAIFREE: A Novel Filtration Technology Targeted at Enhancing the European Healthcare System s Efforts in Rest... At healthcare facilities, there is a strong demand for a new advanced air cleaning technology to prevent infectious diseases such as severe...
Financiado
TOBI: Targeting OBesity driven Inflammation INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7: The TOBI project aims to analyse mechanisms provoking adipokine-mediated crosstalk and an inflammatory drift in obese patients. It will be t...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.